Nicoletta Colombo
Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer.
Overview
Nicoletta Colombo was principal investigator of KEYNOTE-826, which showed pembrolizumab added to chemotherapy with or without bevacizumab improves survival in persistent, recurrent or metastatic cervical cancer, the first immunotherapy survival gain in the disease. She has chaired ESMO-ESGO ovarian cancer consensus conferences and led MITO and ENGOT trials. She directs gynaecologic oncology at IEO.
Pages like this
not linked directly; found by shared links- PersonDomenica Lorusso
Shares Cervical cancer, Pembrolizumab, PD-1, Ovarian cancer and the tags cervical, immunotherapy.
- PersonBradley J. Monk
Shares KEYNOTE-826, VEGF / VEGFR, Cervical cancer, Pembrolizumab and the tag cervical.
- PersonJoaquim Bellmunt
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonBrian I. Rini
Shares VEGF / VEGFR, Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonTimothy F. Cloughesy
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonJalid Sehouli
Shares European Society of Gynaecological Oncology, Cervical cancer, Ovarian cancer.
- PersonArjun V. Balar
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonMartin Reck
Shares Pembrolizumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.